Optical Coherence Tomography-Guided Focal Navigated Laser Photocoagulation in Central Serous Chorioretinopathy: A Non-Inferiority Study.

Am J OphthalmolAug 4, 2026 (epub)
Clinical ResearchOphthalmology

Dmitrii S Maltsev, Alexei N Kulikov, Nikita A Blohin et al.

✦ AI-curated · Sources linked

In 30 seconds

This prospective nonrandomized noninferiority study evaluated the efficacy and safety of en face optical coherence tomography (OCT)-guided laser photocoagulation in patients with nonresolving central serous chorioretinopathy (CSCR). The study found that complete resolution of subretinal fluid (SRF) at 3 months was achieved in 84.6% of the OCT-guided group and 81.3% of the FA-guided group, indicating noninferior outcomes.

Key findings

  • Complete resolution of SRF at 3 months was 84.6% in the OCT-guided group vs 81.3% in the FA-guided group (p = .62).
  • Mean LogMAR BCVA improved from 0.16 to -0.03 in the OCT group (p < .001).
  • Mean central retinal thickness decreased from 379.1 µm to 227.1 µm in the OCT group (p < .001).
  • No adverse events were reported in either treatment group.

Why it matters

The findings suggest that OCT-guided laser photocoagulation is a safe and effective alternative to traditional FA-guided treatment for CSCR, potentially offering clinicians a new tool for managing this condition.

Source

PubMed · PMID 42551779

Published in Am J Ophthalmol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Ophthalmology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.